Results 51 to 60 of about 221,455 (333)

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

New England Journal of Medicine, 2019
BACKGROUND Data regarding the efficacy of treatment with ibrutinib–rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients with previously untreated chronic lymphocytic leukemia (CLL) have ...
T. Shanafelt, X. V. Wang, N. Kay, C. Hanson, S. O'Brien, J. Barrientos, D. Jelinek, E. Braggio, J. Leis, C. C. Zhang, S. Coutre, P. Barr, A. Cashen, A. Mato, Avina K. Singh, Michael P. Mullane, R. Little, H. Erba, R. Stone, M. Litzow, M. Tallman   +20 more
semanticscholar   +1 more source

Rituximab for the treatment of multiple sclerosis: a review

Journal of Neurology, 2021
In the last decades, evidence suggesting the direct or indirect involvement of B cells on multiple sclerosis (MS) pathogenesis has accumulated. The increased amount of data on the efficacy and safety of B-cell-depleting therapies from several studies has
C. Chisari, Eleonora Sgarlata, S. Arena, Simona Toscano, M. Luca, F. Patti   +5 more
semanticscholar   +1 more source

Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing [PDF]

The Korean Journal of Internal Medicine, 2023
Background/Aims Although rituximab, an antiCD20 monoclonal antibody, has dramatically improved the clinical outcomes of diffuse large B-cell lymphoma, rituximab resistance remains a challenge.
Min Ji Jeon, Eun Sang Yu, Chul Won Choi, Dae Sik Kim   +3 more
doaj   +1 more source

Fcγ-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder

Journal of Immunology Research, 2014
We retrospectively analyzed the p.V158F polymorphism of Fcγ-receptor IIIA (FCGR3A, CD16) in patients with PTLD treated with rituximab monotherapy.
Heiner Zimmermann, Theresa Weiland, Jamie P. Nourse, Maher K. Gandhi, Petra Reinke, Ruth Neuhaus, Mohsen Karbasiyan, Barbara Gärtner, Ioannis Anagnostopoulos, Hanno Riess, Ralf U. Trappe, Stephan Oertel   +11 more
doaj   +1 more source

Coding joint: kappa-deleting recombination excision circle ratio and B cell activating factor level: predicting juvenile dermatomyositis rituximab response, a proof-of-concept study

BMC Rheumatology, 2022
Background This pilot study’s primary aim was to determine if oligoclonal B cell expansion in children with Juvenile Dermatomyositis (JDM) predicts response to Rituximab therapy.
Elisa Ochfeld, Victoria Hans, Wil Marin, Najah Ahsan, Gabrielle Morgan, Lauren M. Pachman, Amer Khojah   +6 more
doaj   +1 more source

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

New England Journal of Medicine, 2018
Background The Hu5F9‐G4 (hereafter, 5F9) antibody is a macrophage immune checkpoint inhibitor blocking CD47 that induces tumor‐cell phagocytosis. 5F9 synergizes with rituximab to eliminate B‐cell non‐Hodgkin's lymphoma cells by enhancing macrophage ...
R. Advani, I. Flinn, L. Popplewell, A. Forero, N. Bartlett, N. Ghosh, J. Kline, M. Roschewski, A. LaCasce, G. Collins, T. Tran, J. Lynn, James Y. Chen, J. Volkmer, B. Agoram, Jie Huang, R. Majeti, I. Weissman, C. Takimoto, Mark P. Chao, Sonali M. Smith   +20 more
semanticscholar   +1 more source

Update on rituximab [PDF]

Annals of the Rheumatic Diseases, 2005
Rituximab is a chimeric monoclonal antibody that was developed for the treatment of B cell lymphomas.1 It is directed against the CD20 cell surface molecule.2 CD20 is a tetraspan membrane protein that is present only on B cells, and is expressed initially at the immature B cell stage, remaining until the final differentiation into plasma cells.
openaire   +2 more sources

Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis

Neurology: Neuroimmunology & Neuroinflammation, 2021
Background and Objectives To determine the real-world use of rituximab in autoimmune encephalitis (AE) and to correlate rituximab treatment with the long-term outcome.
F. Thaler, Luise Zimmermann, S. Kammermeier, C. Strippel, M. Ringelstein, A. Kraft, K. Sühs, Jonathan Wickel, C. Geis, R. Markewitz, C. Urbanek, C. Sommer, K. Doppler, Loana Penner, J. Lewerenz, Rosa Rössling, Carsten Finke, H. Prüss, Nico Melzer, K. Wandinger, F. Leypoldt, T. Kümpfel   +21 more
semanticscholar   +1 more source

Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys. [PDF]

PLoS ONE, 2013
The CD20-specific monoclonal antibody rituximab (MabThera(®), Rituxan(®)) is widely used as the backbone of treatment for patients with hematologic disorders. Intravenous administration of rituximab is associated with infusion times of 4-6 hours, and can
Cheng-Ping Mao, Martin R Brovarney, Karim Dabbagh, Herbert F Birnböck, Wolfgang F Richter, Christopher J Del Nagro   +5 more
doaj   +1 more source

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

New England Journal of Medicine, 2010
BACKGROUND Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis for 40 years.
J. Stone, P. Merkel, R. Spiera, P. Seo, C. A. Langford, G. S. Hoffman, C. Kallenberg, E. S. St Clair, A. Turkiewicz, N. Tchao, L. Webber, Lin-Na Ding, Lourdes P. Sejismundo, Kathleen Mieras, D. Weitzenkamp, D. Ikle, V. Seyfert-Margolis, Mark Mueller, P. Brunetta, Nancy B. Allen, F. Fervenza, D. Geetha, K. Keogh, E. Kissin, P. Monach, T. Peikert, C. Stegeman, S. Ytterberg, U. Specks   +28 more
semanticscholar   +1 more source